Head-to-head comparison of ¹⁸F-FDG versus ¹⁸F-FAPI-74 PET in radioactive-iodine refractory differentiated thyroid cancer patients.

IF 0.9 4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Hellenic journal of nuclear medicine Pub Date : 2025-04-07 DOI:10.1967/s002449912780

Panayiotis Hadjitheodorou, Wolfgang Roll, Emmanouil Alevroudis, Kyriaki Kyrou, Giorgos Adamou, Andreas Fesas, Mohammad Reza Pourkhessalian, Charalambia Kalogirou, Ioannis Tsechelidis, Alexis Vrachimis

{"title":"Head-to-head comparison of 18F-FDG versus 18F-FAPI-74 PET in radioactive-iodine refractory differentiated thyroid cancer patients.","authors":"Panayiotis Hadjitheodorou, Wolfgang Roll, Emmanouil Alevroudis, Kyriaki Kyrou, Giorgos Adamou, Andreas Fesas, Mohammad Reza Pourkhessalian, Charalambia Kalogirou, Ioannis Tsechelidis, Alexis Vrachimis","doi":"10.1967/s002449912780","DOIUrl":null,"url":null,"abstract":"Objective: Fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) was reported to outperform fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT in thyroid cancer in heterogenous patient collectives. This interim analysis of a prospective study aims to determine whether 18F-FAPI-74 is superior to 18F-FDG PET/CT in the distinct subgroup of radioactive-iodine (RAI)-refractory differentiated thyroid cancer (DTC).Subjects and methods: Ten patients with recurrent DTC, detected by elevated thyroglobulin, negative RAI-scan after thyroidectomy and RAI-therapy were prospectively included. All patients underwent 18F-FAPI-74 and 18F-FDG PET/CT. The diagnostic performances were compared on a per-patient and per-lesion basis.Results: Fluorine-18-FAPI-74 PET/CT missed tumour recurrence in one patient. Fluorine-18-FDG PET/CT revealed more metastases in three patients. No management change following 18F-FAPI-74 PET/CT was documented. On a per-lesion analysis, the quantitative uptake values were significantly higher for 18F-FDG than 18F-FAPI-74 in all metastases (18F-FDG: median tumor to background ratio-TBRmax: 3.05 (1.02-9.55), 18F-FAPI-74: median TBRmax: 1.09 (0.38-5.09); P<0.001) (18F-FDG: median TBRmean: 1.71 (0.65-11.53), 18F-FAPI-74: median TBRmean: 0.64 (0.24-3.20). The detection rate was significantly higher for 18F-FDG (29/71) compared to 18F-FAPI-74 PET/CT (13/71, P<0.001).Conclusion: Fluorine-18-FDG-PET/CT outperforms 18F-FAPI-74 PET/CT in RAI-refractory DTC in this prospective analysis.","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hellenic journal of nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1967/s002449912780","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) was reported to outperform fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) PET/CT in thyroid cancer in heterogenous patient collectives. This interim analysis of a prospective study aims to determine whether ¹⁸F-FAPI-74 is superior to ¹⁸F-FDG PET/CT in the distinct subgroup of radioactive-iodine (RAI)-refractory differentiated thyroid cancer (DTC).

Subjects and methods: Ten patients with recurrent DTC, detected by elevated thyroglobulin, negative RAI-scan after thyroidectomy and RAI-therapy were prospectively included. All patients underwent ¹⁸F-FAPI-74 and ¹⁸F-FDG PET/CT. The diagnostic performances were compared on a per-patient and per-lesion basis.

Results: Fluorine-18-FAPI-74 PET/CT missed tumour recurrence in one patient. Fluorine-18-FDG PET/CT revealed more metastases in three patients. No management change following ¹⁸F-FAPI-74 PET/CT was documented. On a per-lesion analysis, the quantitative uptake values were significantly higher for ¹⁸F-FDG than ¹⁸F-FAPI-74 in all metastases (¹⁸F-FDG: median tumor to background ratio-TBRmax: 3.05 (1.02-9.55), ¹⁸F-FAPI-74: median TBRmax: 1.09 (0.38-5.09); P<0.001) (¹⁸F-FDG: median TBRmean: 1.71 (0.65-11.53), ¹⁸F-FAPI-74: median TBRmean: 0.64 (0.24-3.20). The detection rate was significantly higher for ¹⁸F-FDG (29/71) compared to ¹⁸F-FAPI-74 PET/CT (13/71, P<0.001).

Conclusion: Fluorine-18-FDG-PET/CT outperforms ¹⁸F-FAPI-74 PET/CT in RAI-refractory DTC in this prospective analysis.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Hellenic journal of nuclear medicine 医学-核医学

CiteScore

1.40

自引率

6.70%

发文量

审稿时长

>12 weeks

期刊介绍： The Hellenic Journal of Nuclear Medicine published by the Hellenic Society of Nuclear Medicine in Thessaloniki, aims to contribute to research, to education and cover the scientific and professional interests of physicians, in the field of nuclear medicine and in medicine in general. The journal may publish papers of nuclear medicine and also papers that refer to related subjects as dosimetry, computer science, targeting of gene expression, radioimmunoassay, radiation protection, biology, cell trafficking, related historical brief reviews and other related subjects. Original papers are preferred. The journal may after special agreement publish supplements covering important subjects, dully reviewed and subscripted separately.